Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · May 01, 2023

MS, Disease-Modifying Drugs, and the Risk for Adverse Perinatal and Pregnancy Outcomes

Multiple Sclerosis (Houndmills, Basingstoke, England)


Additional Info

Disclosure statements are available on the authors' profiles:

Multiple Sclerosis (Houndmills, Basingstoke, England)
Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
Mult. Scler. 2023 Apr 18;[EPub Ahead of Print], K Fink, A Gorczyca, P Alping, S Englund, S Farmand, AM Langer-Gould, F Piehl, K McKay, T Frisell, N Razaz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading